The company's product, CAP-100, is an anti-CCR7 antibody that targets the overexpression of the chemokine receptor CCR7 in various cancers. This overexpression is associated with poor prognosis and short survival in hematological and solid malignancies. CAP-100 has a unique mechanism of action that blocks tumor cell migration to the lymph nodes and inhibits tumor cell survival. Currently in preclinical development, CAP-100 has shown promising results in prolonging survival and inhibiting cancer cell migration in animal models of B-cell and T-cell lymphomas.